Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluorescein. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.58 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.58 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | GAPDH | P04406 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | STAT6 | P42226 | 1/20 | 0.58 |
| ▸ | PI4KA | P42356 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.58 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.58 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712498 | 0.84 | ABCB1 (0.58) | ADORA3ADORA2AADORA2BADORA1SMN1; SMN2 | |
| SCHEMBL6709321 | 0.84 | NT5E (0.57) | ADORA3ADORA2AADORA2BADORA1SMN1; SMN2 | |
| Fluorescein SCHEMBL1434704 | 0.81 | STING1 (0.65) | KMT2ABLM | |
| Adenosine SCHEMBL22323627 | 0.78 | ADORA3 (0.83) | ADORA3MEN1KMT2ASLC29A1DPP4 | |
| Fluorescein SCHEMBL3485550 | 0.78 | FTO (0.69) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| Fluorescein SCHEMBL1034246 | 0.78 | FTO (0.69) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| Adenosine SCHEMBL27823321 | 0.77 | ADORA3 (0.89) | ADORA3MEN1KMT2ASLC29A1DPP4 | |
| Adenosine SCHEMBL28830011 | 0.77 | ADORA3 (0.87) | ADORA3MEN1KMT2ASLC29A1DPP4 | |
| Adenosine SCHEMBL1668795 | 0.76 | ADORA3 (0.66) | ADORA3MEN1KMT2ASLC29A1DPP4 | |
| Adenosine SCHEMBL23420216 | 0.76 | ADORA3 (1.00) | ADORA3MEN1KMT2ASLC29A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751151-A1 | PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1740590-A1 | PYRAZOLO [3,4- b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1735314-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090354-A1 | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090348-A1 | PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1539753-A2 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |